Application of ZFP36L2 gene in treating and / or preventing radiation damage
By adjusting the expression level of ZFP36L2 gene in macrophages, the problems of mitochondrial dysfunction and systemic inflammatory response of macrophages during radiation damage are solved, and the effect of reducing cell damage and improving healing ability is achieved, providing new for radiation damage treatment. scientific basis.
Patent Information
- Application Number
- CN202411146999.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-21
- Publication Date
- 2024-11-05
- Estimated Expiration
- 2044-08-21
AI Technical Summary
The prior art lacks effective methods in the treatment and/or prevention of radiation damage, especially solutions for macrophage mitochondrial dysfunction and systemic inflammatory responses.
By adjusting the expression level of the ZFP36L2 gene in macrophages, drugs are prepared to resist radiation-induced mitochondrial dysfunction and cell damage to alleviate systemic inflammatory responses using lentiviruses overexpressed by ZFP36L2 or other biological materials that promote ZFP36L2 expression.
Significantly slows down radiation damage, improves cell scratch healing ability, reduces mitochondrial reactive oxygen accumulation, reduces cell apoptosis, and significantly improves tissue damage and inflammatory response in the radiation environment, providing a new strategy for radiation damage treatment.
Smart Images

Figure CN118649252B_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the field of biomedicine, and in particular to application of ZFP36L2 gene in treating and / or preventing radiation damage. Background Art
[0002] Radiation, as a strong environmental stressor, can cause extensive damage to the cell and tissue structures of organisms. In the body's stress response to radiation, macrophages play a vital dual role: on the one hand, they promote the repair of damaged tissues, and on the other hand, they may aggravate the damage in some cases. It is worth noting that the mitochondrial function of macrophages plays a central role in the regulation of their metabolic state and immune function. In addition, the interaction between macrophages and parenchymal cells is complex and profound, significantly shaping the body's response and recovery process to radiation damage.
[0003] At the molecular level, ZFP36L2 (Zinc finger protein 36, C3H type-like 2) belongs to the ZFP36 protein family and undertakes the key task of regulating the RNA post-transcription process. This protein accurately maintains the stability of gene expression through its unique zinc finger structure. In terms of immune regulation, studies have shown that the ZFP36 family can significantly affect the stability of T cell messenger RNA, thereby inhibiting the proliferation and activation of T cells. In terms of maintaining mitochondrial function, ZFP36L2 can effectively alleviate cell damage in a hypoxic environment by regulating the fusion and fission process of mitochondria. However, the effect of the ZFP36L2 gene in treating and / or preventing radiation damage has not been reported. Summary of the invention
[0004] The purpose of the present invention is to provide the use of ZFP36L2 gene in treating and / or preventing radiation damage.
[0005] The inventors surprisingly found in their research that by adjusting the expression level of ZFP36L2 in macrophages, it is possible to resist radiation-induced macrophage mitochondrial dysfunction and reduce radiation-induced cell damage and systemic inflammatory response. Based on this, the inventors have completed the following invention.
[0006] The first aspect of the present invention is to provide the use of ZFP36L2 in the following (A1) or (A2) or (A3): (A1) preparing a drug for treating and / or preventing radiation damage; (A2) preparing a drug for resisting radiation-induced mitochondrial dysfunction; (A3) preparing a drug for treating radiation-induced vascular endothelial damage.
[0007] In this application, the drug includes an agent that promotes the expression of ZFP36L2; the inventors discovered the result in an experiment through a ZFP36L2 overexpression lentivirus, but those skilled in the art clearly know that other agents that promote the expression of ZFP36L2, such as small molecule compounds or bioactive molecules, can also easily obtain the same result or a similar effect. Based on this, the use of other agents that can promote the expression of ZFP36L2 also falls within the scope of protection of the present invention.
[0008] In this application, the reagent includes a biological material overexpressing ZFP36L2; the inventor discovered the result in an experiment through a ZFP36L2 overexpressing lentivirus, but those skilled in the art clearly know that in addition to the ZFP36L2 overexpressing lentivirus vector, other ZFP36L2 overexpressing biological materials, such as a ZFP36L2 overexpressing recombinant plasmid or adeno-associated virus, can also easily obtain the same result or a similar effect. Based on this, the use of other ZFP36L2 overexpressing biological materials also falls within the scope of protection of the present invention.
[0009] In this application, the biological material includes any one of the following (1) to (4): (1) ZFP36L2 gene, whose nucleotide sequence is shown in SEQ ID NO.1; (2) plasmid, including the ZFP36L2 gene; (3) lentivirus, including the plasmid; (4) host cell, including the plasmid or lentivirus; according to an embodiment of the present invention, the plasmid is pGPG-Lenti CMV Puro; the packaging plasmid of the lentivirus is psPAX and pMD2.G; when the host cell is 293T cell or macrophage, better effect can be achieved.
[0010] In this application, the drug treatment and / or prevention of radiation damage is achieved by the following (B1) or (B2) or (B3): (B1) resisting radiation-induced mitochondrial dysfunction; (B2) treating radiation-induced vascular endothelial damage; (B3) reducing radiation-induced cell damage and systemic inflammatory response. Further, the resistance to radiation-induced mitochondrial dysfunction is achieved by overexpressing ZFP36L2 to reduce radiation-induced mitochondrial swelling and vacuolation, and reducing the accumulation of mitochondrial reactive oxygen species. The treatment of radiation-induced vascular endothelial damage is achieved by overexpressing ZFP36L2 to improve the scratch healing ability and angiogenesis ability of human umbilical vein endothelial cells and reduce cell apoptosis; the present invention proposes for the first time to treat and / or prevent radiation damage by promoting ZFP36L2 expression.
[0011] The second aspect of the present invention is to provide a drug for treating and / or preventing radiation damage, which includes a biomaterial overexpressing ZFP36L2 and a pharmaceutically acceptable excipient. It can be understood by those skilled in the art that the excipients include but are not limited to: stabilizers, used to maintain the structural integrity and stability of the biomaterial overexpressing ZFP36L2, such as glucose, glycerol, etc.; transfection enhancers, used to enhance the efficiency of the biomaterial overexpressing ZFP36L2 entering cells, such as polyethyleneimine; protective agents, used to protect the stability and activity of the biomaterial overexpressing ZFP36L2 during the preparation and storage process, such as low-temperature stabilizers and buffers; solvents and regulators, used to adjust the solubility of the biomaterial overexpressing ZFP36L2 and the preparation process of the drug preparation, such as water and hydrochloric acid.
[0012] In the drug, the biological material includes any one of the following (1) to (4): (1) ZFP36L2 gene, whose nucleotide sequence is shown in SEQ ID NO.1; (2) plasmid, including the ZFP36L2 gene; (3) lentivirus, including the plasmid; (4) host cell, including the plasmid or lentivirus; according to an embodiment of the present invention, the plasmid is pGPG-Lenti CMV Puro; the packaging plasmid of the lentivirus is psPAX and pMD2.G; when the host cell is 293T cell or macrophage, better effect is achieved.
[0013] The third aspect of the present invention is to provide a macrophage transplant mouse model that overexpresses ZFP36L2 to resist radiation damage for use in screening drugs for treating and / or preventing radiation damage. In the stress response of the body to radiation, macrophages, as the main line of defense of immunity, play a complex role in radiation damage. The present invention proposes for the first time to construct a macrophage transplant mouse model that resists radiation damage by promoting ZFP36L2 expression. This model will help promote the research of more radiation damage-related drugs and provide a model basis for the research and development of drugs for treating and / or preventing radiation damage and target research.
[0014] In this application, the construction of the macrophage transplantation mouse model includes the following steps:
[0015] S1. Construct a plasmid for overexpression of ZFP36L2. The gene sequence fragment of ZFP36L2 is as described in SEQ ID NO. 1. The gene sequence is cloned into the vector pGPG-Lenti CMV Puro via 5' XbaI and 3' SalI, and the ZFP36L2 overexpression plasmid is packaged by lentivirus.
[0016] S2. Primary peritoneal macrophages were extracted from donor mice for culture. ZFP36L2 was overexpressed by infecting the above-mentioned lentivirus, and peritoneal macrophages with stable expression of ZFP36L2 were selected, and irradiated for stimulation; the irradiated peritoneal macrophages were reinfused into the peritoneal cavity of recipient mice to obtain a macrophage transplantation mouse model.
[0017] The significant advantages of the present invention are:
[0018] This invention reveals for the first time the role of ZFP36L2 overexpression in mitigating radiation damage. By adjusting the expression level of ZFP36L2 in macrophages, radiation-induced mitochondrial dysfunction can be resisted. In vitro experiments have verified that the supernatant of macrophages with ZFP36L2 overexpression significantly improves the scratch healing ability of HUVEC under irradiation conditions.
[0019] The present invention further demonstrated through macrophage transplantation mouse experiments that ZFP36L2-overexpressing macrophages can significantly reduce the damage to the abdominal tissue of transplanted mice under radiation environment, and have the ability to inhibit immune inflammatory response, which provides a scientific basis for the development of potential treatment strategies in the future and has broad clinical application prospects. BRIEF DESCRIPTION OF THE DRAWINGS
[0020] In order to more clearly illustrate the specific implementation methods of the present invention or the technical solutions in the prior art, the drawings required for use in the specific implementation methods or the description of the prior art will be briefly introduced below. Obviously, the drawings described below are some implementation methods of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying creative work.
[0021] Figure 1 The empty plasmid used to construct the ZFP36L2 overexpression plasmid of the present invention and the plasmid map of the constructed ZFP36L2 overexpression plasmid; wherein, Figure A is the plasmid map of the empty plasmid pGPG-Lenti CMV Puro, and Figure B is the plasmid map of the ZFP36L2 overexpression plasmid;
[0022] Figure 2 Analysis of ZFP36L2 expression in peritoneal macrophages in different treatment groups; Figure A is a Western blot analysis of intracellular ZFP36L2 levels; Figure B is Image Lab grayscale intensity statistics;
[0023] Figure 3 Transmission electron microscopy was used to observe the changes of mitochondria and internal structures in peritoneal macrophages in different treatment groups;
[0024] Figure 4Figure 1 is the fluorescence staining analysis of peritoneal macrophages in different treatment groups; Figure A is the MitoSOX fluorescence microscope image of peritoneal macrophages at 630× magnification; Figure B is the MitoTracker fluorescence microscope image of peritoneal macrophages at 630× magnification; Figure C is the MitoSOX fluorescence intensity statistics in Figure A; Figure D is the MitoTracker fluorescence intensity statistics in Figure B;
[0025] Figure 5 The migration ability of peritoneal macrophages in different treatment groups is detected; Figure A is a representative picture of the scratch test of different treatment groups at 0h, 24h, 48h, and 72h; Figure B is the statistics of the migration ability of different treatment groups in Figure A;
[0026] Figure 6 Figure 3 shows the angiogenesis of HUVECs in different treatment groups at 0h, 6h, 15h, and 24h;
[0027] Figure 7 Apoptosis analysis of HUVEC cells in different treatment groups;
[0028] Figure 8 For the macrophage transplantation mouse model;
[0029] Fig. 9 H&E staining images of peritoneal tissues in different treatment groups; arrows in the figure indicate positive signals;
[0030] Fig.10 The spleen weights of mice in different treatment groups were measured and counted;
[0031] Fig.11 TUNEL staining was used to detect apoptosis of mouse spleen cells. DETAILED DESCRIPTION
[0032] The technical solution of the present invention will be clearly and completely described below in conjunction with the embodiments. Obviously, the described embodiments are part of the embodiments of the present invention, rather than all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.
[0033] The terms "first", "second" and "third" in the present invention are only used for descriptive purposes and cannot be understood as indicating or implying relative importance or implicitly indicating the number of indicated technical features. Therefore, the features defined as "first", "second" and "third" can explicitly or implicitly include multiple features. In the description of this application, the meaning of "multiple" is at least two, such as two, three, etc., unless otherwise clearly and specifically defined. All directional indications (such as up, down, left, right, front, back...) in the embodiments of the present application are only used to explain the relative position relationship, movement, etc. between the components under a certain specific posture (as shown in the accompanying drawings). If the specific posture changes, the directional indication also changes accordingly. In addition, the terms "including" and "having" and any of their variations are intended to cover non-exclusive inclusions. For example, a process, method, system, product or device that includes a series of steps or modules is not limited to the listed steps or modules, but optionally also includes steps or modules that are not listed, or optionally also includes other steps or modules inherent to these processes, methods, products or devices.
[0034] Reference to "embodiments" herein means that the specific features, structures, or characteristics described in conjunction with the embodiments may be included in multiple embodiments of the present application. The appearance of the phrase in various places in the specification does not necessarily refer to the same embodiment, nor is it an independent or alternative embodiment that is mutually exclusive with other embodiments. It is explicitly and implicitly understood by those skilled in the art that the embodiments described herein may be combined with other embodiments.
[0035] The design principle of the embodiment of the present invention is that macrophages, as the main line of defense of immunity, play a complex role in radiation damage. Macrophages are not only involved in the repair process of damage, but may also aggravate the degree of damage. First, the inventors explored the effects of radiation on macrophage morphology and signaling pathways. It was observed that after receiving 2, 5 and 10 Gy irradiation stimulation, the morphology of primary mouse peritoneal macrophages changed significantly within 24 hours, from the classic cobblestone-like to a polarized state with elongated pseudopodia, the pseudopodia length increased significantly, and the cells showed a more dispersed and extended morphology, and this change was more significant as the irradiation intensity increased. It is suggested that macrophages undergo significant morphological changes in response to radiation damage, which may be related to the transformation of their functional state. In order to further understand the molecular mechanism of the effect of irradiation stimulation on macrophages, the inventors performed RNA-seq analysis on primary mouse peritoneal macrophages treated with 10 Gy irradiation. The results showed that after irradiation, the expression of a large number of genes in macrophages changed significantly, including 687 upregulated genes and 311 downregulated genes. The changes in P53-related signaling pathways and amino acid biosynthesis pathways were the most significant. At the transcription factor level, the inventors observed that the expression of transcription factors related to the zinc finger gene family was significantly upregulated. C2H2 is a family of proteins that regulate gene expression by interacting with DNA, RNA or other proteins through its zinc finger domain. In this family, ZFP36L2, as a member, promotes the degradation of mRNA by binding to specific AU-rich elements on the 3' untranslated region of mRNA, thereby regulating gene expression. Western Blot detection further verified this finding. After irradiation, the expression of ZFP36L2 protein in the macrophage cell line RAW264.7 and primary mouse peritoneal macrophages was significantly upregulated. This suggests that ZFP36L2 may play an important regulatory role in the response of macrophages to radiation stress and participate in signal transduction in macrophages under radiation conditions.
[0036] Based on the above reasons, the present inventors provide a use of ZFP36L2 in treating and / or preventing radiation damage; through ZFP36L2 gene overexpression in macrophages and macrophage transplantation experiments, the potential of ZFP36L2 in treating and / or preventing radiation damage is further verified.
[0037] It should be noted that the experimental methods used in the embodiments of the present invention, unless otherwise specified, are all conventional methods, and the reagents and materials used, unless otherwise specified, can be obtained from commercial channels.
[0038] The experimental animal breeding standards involved in the embodiments of the present invention are as follows: mice were purchased from Jackson Laboratory and Chengdu Dashuo Experimental Animal Co., Ltd.; they were raised in an environment with alternating light and dark, a lighting time of 12 h (lights on at 08:00), a humidity of 50%, and a room temperature of 25°C, and they were allowed to drink water and eat freely during the breeding period.
[0039] The peritoneal macrophage culture method used in the embodiment of the present invention is as follows: take 6-8 week old C57BL / 6 strain wild-type mice, inject thioglycolate broth (weigh 21g dehydrated dry powder, add 1L distilled water. Heat to boiling, stir until the powder is completely dissolved, and heat in an autoclave at 121°C for 15 min for sterilization) into the mouse peritoneum to promote the aggregation of macrophages; three days later, the mouse was euthanized by cervical dislocation, and the skin and peritoneum were separated by blunt dissection. Use a 5ml syringe to inject DMEM medium without FBS into the mouse peritoneum, gently massage the abdomen, and recover the injected DMEM medium, and repeat this five times; add the extracted cells to the complete DMEM medium, centrifuge at 1500 rpm for 15min, discard the supernatant, and resuspend the resulting cell pellet with DMEM medium (supplemented with 10% FBS, 100 U / ml penicillin and 100 µg / ml streptomycin), replace the medium after 24h, and incubate at 37°C and 5% CO 2 The cells were cultured and grown in a cell culture incubator.
[0040] The expression vector used in the embodiments of the present invention is:
[0041] The empty plasmid was pGPG-Lenti CMV Puro; Wuhan GeneWeiZhi Biotechnology Co., Ltd. was commissioned to synthesize the sequence, and the NC insertion sequence was irrelevant. The insertion sequence of Zfp36l2 overexpression (NCBI Gene ID: 12193) was:
[0042]
[0043] Embodiment 1
[0044] This example verifies the effect of ZFP36L2 overexpression on macrophage mitochondria;
[0045] 1.1. Construction of ZFP36L2 overexpressing macrophage cell line;
[0046] 1.1.1. Construction of ZFP36L2 overexpression plasmid;
[0047] (1) pGPG-Lenti CMV Puro was used as an empty vector plasmid. This plasmid contains the CMV promoter and the Puro resistance gene. The plasmid map is shown in Figure 1 A;
[0048] (2) The insert fragment is the Zfp36l2 gene containing a 6His tag, which was commissioned to Wuhan GeneWeizhi Co., Ltd. for synthesis, and the sequence is shown in SEQ ID NO:1; the insert fragment is designed as XbaI - 6His - Zfp36l2 - SalI, and corresponding restriction endonuclease sites are added at the 5' end (XbaI) and the 3' end (SalI);
[0049] (3) Use XbaI and SalI restriction endonucleases to digest the pGPG-Lenti CMV Puro plasmid, linearize the plasmid, and then recover and purify it by gel;
[0050] (4) The cloned Zfp36l2 insert fragment was ligated with the linearized pGPG-Lenti CMV Puro plasmid; the ligated product was transformed into competent cells (DH5α), and positive clones containing Zfp36l2 insertion were screened by Ampicillin resistance;
[0051] (5) Select 6 monoclonal clones with good growth conditions for monoclonal PCR identification to confirm the accuracy and direction of Zfp36l2 insertion; after confirming the positive clones, perform plasmid extraction;
[0052] (6) Sequence the plasmid extracted from the positive clone to verify the integrity of the Zfp36l2 insertion and the correct construction of the plasmid. After confirming the sequencing results, the successfully constructed ZFP36L2 overexpression plasmid (i.e., Zfp36l2 in pGPG-Lenti CMV Puro) was determined. The plasmid map is shown in Figure 1 B.
[0053] 1.1.2. Construction of ZFP36L2 overexpression lentivirus;
[0054] (1) 5×10 5293T cells were seeded in a 6 cm culture dish;
[0055] (2) 24 hours later, the viral packaging plasmids psPAX, pMD2.G, and the sequenced Zfp36l2 inpGPG-Lenti CMV Puro plasmid were transferred into 293T cells using PEI;
[0056] (3) 72 h after transfection, the supernatant was collected and centrifuged at 4000 rpm at 4°C for 4 min. The resulting supernatant was the lentivirus containing the Zfp36l2 overexpression plasmid.
[0057] (4) Filter the collected supernatant using a 0.45 μm filter membrane to remove cell debris;
[0058] (5) Centrifuge the filtered viral supernatant at 20,000 × g for 4 h at 4°C using an ultracentrifuge;
[0059] (6) Gently resuspend the virus pellet after centrifugation with PBS or an appropriate buffer to obtain a virus concentrate;
[0060] (7) Determine the virus titer by real-time PCR; ensure that the virus titer is between 10E8-10E9.
[0061] Cell transfection
[0062] The collected virus concentrate was added to the culture medium of peritoneal macrophages and incubated at 37°C and 5% CO 2 After 72 hours of culture, the culture medium was replaced with new one and cultured for another 24 hours. The non-transfected peritoneal macrophages were eliminated by puromycin screening to obtain a macrophage cell line with stable ZFP36L2 overexpression.
[0063] 1.2. Cell grouping
[0064] Peritoneal macrophages overexpressing irrelevant sequences were used as the negative control group (NC group), and the peritoneal macrophages in the negative control group and the peritoneal macrophages overexpressing ZFP36L2 were irradiated with 10 Gy. After incubation in a cell culture incubator at 37°C for 24 hours, the cells were collected for detection, and the cells that were not irradiated were used as the control (Control).
[0065] Western blot detection
[0066] The above cell samples were lysed using RIPA cell lysis buffer and protease inhibitors; the protein concentration was determined using a BCA protein concentration detection kit; the protein in each group of samples was adjusted to the same concentration and volume according to the protein concentration measured by BCA to ensure that the protein content of each group of samples was consistent; each sample was mixed evenly with SDS sample buffer and boiled for 10 minutes to denature the protein; the pre-made SDS-PAGE gel was fixed in the electrophoresis tank; the treated protein sample was added to the sample well of the gel, and then an appropriate amount of pre-stained protein marker was added to both ends of the protein sample; two-step electrophoresis was performed, first at 80V for 30 minutes to concentrate the protein, and then at 120V for 80 min, until the bromophenol blue dye moves forward to the bottom of the gel; cut the gel containing the target protein and soak it in the transfer solution; assemble the transfer clip in the order of filter paper-gel-NC membrane-filter paper-sponge, transfer to the transfer tank, and transfer the membrane in an ice bath at 100V for 60 minutes; after the transfer is completed, take out the NC membrane and place it in 5% BSA, and block it on a shaker at room temperature for 60 minutes; after blocking, place the NC membrane in the antibody incubation box with the protein facing up, add the diluted primary antibody, and incubate it on a constant temperature shaker at 4°C overnight; wash the NC membrane 3 times with PBST, 10 minutes each time; prepare the corresponding secondary antibody solution according to the species of the primary antibody, and incubate it at room temperature for 1 hour; wash the membrane 3 times with PBST, 10 minutes each time; place the membrane in the tray of the BioRad gel imager, and use Image-Lab software to analyze the grayscale value of the target band.
[0067] 1.4. Transmission electron microscopy
[0068] The above cell samples were collected into centrifuge tubes and centrifuged at 1500 rpm for 5 minutes; the supernatant was discarded, and 1% glutaraldehyde fixative was slowly added along the wall of the centrifuge tube with a pipette. After resuspending, the cells were allowed to stand at 4°C for 5 minutes; the cells were then transferred to a 1.5 mL centrifuge tube, centrifuged at 10000-13000 rpm for 10 minutes, and 3% glutaraldehyde fixative was slowly added along the wall of the tube with a pipette; the samples were refrigerated at 4°C and sent to a third-party testing agency (Chengdu Lilai Biotechnology Co., Ltd.) for testing, and the mitochondria and internal structures in the cells were observed using a transmission electron microscope.
[0069] 1.5. Mitochondrial ROS and MitoTracker detection
[0070] Place a sterilized glass slide at the bottom of each well of a 24-well plate and inoculate each well with 3×10^ 5cells; the MitoSOX probe was diluted to 5 μM, and the MitoTracker® Red CMXRos dye was diluted to 200 nM with complete culture medium; the diluted MitoSOX and MitoTracker probes were added to the cells and incubated in a cell culture incubator at 37°C in the dark for 10 min; after the incubation, the cells were washed with PBS to remove excess probes; 200 μL of 10 μg / mL Hoechst dye was added to each well and incubated at room temperature in the dark for 3 min; 10 μL of anti-fluorescence quenching mounting medium was dropped on the slide, and the coverslip with stained cells was placed face down on the mounting medium; after drying, it was stored at 4°C in the dark; the excitation wavelength of MitoSOX was set to 510 nm and the emission wavelength was 590 nm; the excitation wavelength of MitoTracker was set to 579 nm and the emission wavelength was set to 599 nm, and images were taken using a fluorescence microscope to observe the stained cells.
[0071] 1.6. Experimental results
[0072] Figure 2 A is Western blot analysis of ZFP36L2 expression levels in peritoneal macrophages;
[0073] Figure 2 B is the grayscale intensity statistics of Image Lab;
[0074] Figure 3 Transmission electron micrographs of mitochondria and internal structures in peritoneal macrophages;
[0075] Figure 4 A is a fluorescence microscope image of MitoSOX in peritoneal macrophages;
[0076] Figure 4 B is the MitoTracker fluorescence microscope image of peritoneal macrophages;
[0077] Figure 4 C is Figure 4 Statistics of MitoSOX fluorescence intensity in A;
[0078] Figure 4 D is Figure 4 Statistics of MitoTracker fluorescence intensity in B;
[0079] according to Figure 2 A and Figure 2 As shown in B, the expression of ZFP36L2 protein in ZFP36L2-overexpressing macrophages was significantly upregulated, indicating that the ZFP36L2-overexpressing macrophage cell line was successfully constructed;
[0080] according to Figure 3As shown, the swelling and vacuolization of mitochondria in ZFP36L2-overexpressing macrophages were significantly milder than those in the negative control group (NC group);
[0081] according to Figure 4 A to Figure 4 As shown in D, the quantitative fluorescence staining of MitoSOX and MitoTracker in the ZFP36L2 overexpression group was reduced compared with that in the negative control group;
[0082] In summary, irradiation stimulation (10Gy) causes mitochondrial swelling and vacuolization in peritoneal macrophages, and significantly increases the degree of activation and accumulation of reactive oxygen species. However, overexpression of Zfp36l2 significantly reduces these mitochondrial damage characteristics in peritoneal macrophages, including reducing the accumulation and activation state of mitochondrial reactive oxygen species. This indicates that overexpression of Zfp36l2 resists radiation-induced mitochondrial dysfunction and can inhibit excessive mitochondrial stress activation caused by macrophage irradiation stress. Zfp36l2 is expected to be a new target for new drugs or therapeutic strategies in the treatment of radiation damage.
[0083] Embodiment 2
[0084] In vitro experiments were conducted to study the effects of ZFP36L2-overexpressing macrophage supernatant on the function of human umbilical vein endothelial cells (HUVEC, CRL-1730);
[0085] 2.1 Preparation of conditioned medium:
[0086] The macrophages overexpressing ZFP36L2 in the above Example 1 were inoculated in a 10 cm culture dish, and when the cells were fused to 70% to 80%, they were replaced with complete culture medium. After 48 hours, 10 Gy of radiation stimulation was given. After 24 hours, the supernatant of the macrophages overexpressing ZFP36L2 was collected and used as a conditioned medium for human umbilical vein endothelial cells (HUVEC); negative control group (NC group): in the same manner as above, the supernatant of peritoneal macrophages overexpressing irrelevant sequences was prepared and used as a conditioned medium; and cells not stimulated by irradiation were used as controls;
[0087] 2.2. Cell migration ability detection
[0088] (1) Use a marker pen to evenly draw horizontal lines on the back of the 6-well plate, with 3 lines passing through each well as positioning marks;
[0089] (2) HUVECs were seeded in a 6-well plate. When the cell confluence reached 95%, a 200 μL pipette was used to scratch the well plate as vertically as possible to the horizontal line marked on the back.
[0090] (3) After scratching, HUVECs were placed in a 37°C, 5% CO2 The cells were cultured in a cell culture incubator; images were regularly observed and recorded at 0 h, 24 h, 48 h, and 72 h after culture using an inverted microscope.
[0091] (4) ImageJ software was used to analyze the migration distance of the scratch area to reflect the migration ability of macrophages; migration distance = cell migration area / image width (the dotted line marks the edge of cell migration).
[0092] 2.3. Angiogenesis ability detection
[0093] (1) Add 50 μL of Matrigel matrix to each well of a 96-well plate and incubate at 37°C for 30 min to allow it to solidify into a gel;
[0094] (2) 1×10^ 4 The HUVEC suspension was seeded into the wells containing Matrigel at a density of 10 cells / mL and continued to be cultured at 37°C, 5% CO. 2 Cultured in an incubator;
[0095] (3) Use an inverted microscope to regularly observe and record the formation of capillary-like structures at 6 h, 15 h, and 24 h after culture.
[0096] 2.4. Flow cytometry detection of cell apoptosis
[0097] (1) HUVECs were collected from the conditioned medium after 24 h of culture and washed twice with pre-cooled PBS;
[0098] (2) HUVEC were cultured at 1×10^ 6 cells / mL in 1X binding buffer, and 100 μL of HUVEC suspension (1×10^ 5 Cells) were transferred into a 5 mL culture tube;
[0099] (3) Add 5 μL APC-conjugated Annexin V and 5 μL PI to the culture tube;
[0100] (4) Gently shake the tubes and incubate at room temperature in the dark for 15 min. After incubation, add 400 μL of 1X binding buffer to each tube.
[0101] (5) Analyze the stained cells using flow cytometry within 1 hour, and use appropriate settings to detect APC and PI. Cells that are APC-conjugated Annexin V positive and PI negative indicate early apoptosis, while cells that are APC-conjugated Annexin V positive and PI positive indicate late apoptosis or dead cells.
[0102] 2.5 Experimental results
[0103] Figure 5 A is a representative picture of the scratch test for different treatment groups;
[0104] Figure 5 B is the statistics of migration ability of different treatment groups in Figure A;
[0105] Figure 6 Figure 4 shows the angiogenesis in different treatment groups;
[0106] Figure 7 Apoptosis analysis of HUVEC cells in different treatment groups.
[0107] (1) Based on Figure 5 A and Figure 5 As shown in B, the supernatant of macrophages overexpressing ZFP36L2 significantly improved the scratch healing ability of HUVEC under irradiation conditions, showing significant statistical differences at 24, 48 and 72 h.
[0108] (2) Based on Figure 6 As shown, the supernatant of ZFP36L2-overexpressing macrophages also significantly improved the angiogenic ability of HUVECs, showing significant effects at 6, 15 and 24 h.
[0109] (3) Based on Figure 7 As shown, the flow cytometry results showed that after the supernatant of ZFP36L2-overexpressing macrophages irradiated with 10 Gy acted on HUVEC, the number of APC and PE double-positive cells was significantly reduced compared with the control group, indicating that the supernatant of ZFP36L2-overexpressing macrophages can reduce the apoptosis rate of HUVEC under irradiation conditions.
[0110] In summary, the supernatant of macrophages with overexpression of ZFP36L2 significantly improved the scratch healing ability and angiogenesis ability of HUVEC under irradiation conditions, and reduced cell apoptosis. This shows that the supernatant of macrophages with overexpression of ZFP36L2 has the function of significantly protecting HUVEC under irradiation conditions. ZFP36L2 is expected to counteract radiation-induced vascular endothelial damage by protecting endothelial cell function, promoting cell repair and reducing apoptosis, and has potential therapeutic effects.
[0111] Embodiment 3
[0112] Macrophage transplantation mouse experiments verified the potential of ZFP36L2 in treating and / or preventing radiation damage; experimental mice were C57BL / 6 mice purchased from Jackson Laboratory and Chengdu Dashuo Experimental Animal Co., Ltd., 6-8 weeks old;
[0113] 3.1. Experimental methods, construction of macrophage transplantation mouse model, such as Figure 8 As shown:
[0114] (1) Extracting primary peritoneal macrophages from donor mice according to the above peritoneal macrophage culture method;
[0115] (2) After 24 h of in vitro culture (at 37°C and 5% CO 2 The peritoneal macrophages were inoculated with the ZFP36L2 overexpression lentivirus described in the above example:
[0116] (3) After 72 h of in vitro culture, peritoneal macrophages with stable ZFP36L2 overexpression were collected and irradiated with 10 Gy;
[0117] (4) 24 hours later, the irradiated peritoneal macrophages were infused back into the peritoneal cavity of the recipient mice. The number of cells inoculated per mouse was controlled to be at least 3 × 10 ^5 cells;
[0118] (5) After 7 days of feeding according to the above experimental animal feeding standards, the mice were euthanized and samples were taken to evaluate the inflammatory damage of the recipient mouse tissues;
[0119] The setting of the negative control group (NC) was consistent with that described in the above experimental method, except that the lentivirus overexpressing ZFP36L2 was replaced by a lentivirus overexpressing an irrelevant sequence; and mice transplanted with peritoneal macrophages that were not stimulated by radiation were used as controls (Control).
[0120] 3.2. H&E staining evaluation
[0121] (1) Collect mouse peritoneal tissues and fix them with 4% paraformaldehyde overnight;
[0122] (2) Rinse with running water, and then dehydrate the sample using a gradient ethanol method;
[0123] (3) Wash the cell samples in xylene and then embed them in paraffin;
[0124] (4) Cut the tissue sample into thin slices and make paraffin sections.
[0125] (5) Stain with hematoxylin and eosin (HE), and finally observe and image the sections under a microscope.
[0126] 3.3. Mouse spleen weight measurement
[0127] Mouse spleen index = mouse spleen mass / mouse body weight (g).
[0128] 3.4. TUNEL cell apoptosis detection
[0129] (1) Collect spleen tissue from mice and fix the samples with 4% formaldehyde solution at room temperature for 1 h;
[0130] (2) Wash the samples twice with PBS, 15 min each time;
[0131] (3) Treat the sample with proteinase K (20 μg / mL) at room temperature for 30 min to expose the DNA ends;
[0132] (4) Wash the sample twice again with PBS:
[0133] (5) TUNEL assay solution prepared according to the reference table;
[0134] (6) Add 50 μL of TUNEL detection solution to each sample, ensuring that the tissue section is covered, and incubate in a humidified environment at 37°C for 1 h away from light;
[0135] (7) After incubation, wash the samples three times with PBS, 5 min each time;
[0136] (8) Add DAPI staining solution with a concentration of 1 μg / mL and incubate at room temperature for 5 min;
[0137] (9) Wash the sample with PBS and seal it with anti-fluorescence quenching sealing solution;
[0138] (10) Observe and analyze TUNEL-stained samples under a fluorescence microscope.
[0139] 3.5 Experimental results
[0140] Fig. 9 This is the H&E staining image of mouse peritoneal tissue; the arrows in the figure indicate positive signals;
[0141] Fig.10 The spleen weights of mice in different treatment groups were measured and counted;
[0142] Fig.11 TUNEL staining was used to detect apoptosis of mouse spleen cells;
[0143] (1) Based on Fig. 9 As shown in the figure, the peritoneal tissues of recipient mice transplanted with peritoneal macrophages overexpressing irrelevant sequences after irradiation showed significant pathological changes: irregular structure of duodenal villi and thinning of basal layer; disappearance of liver lobule structure, accompanied by granulocyte infiltration and small hemorrhagic areas; fatty vacuolar degeneration of pancreatic islet cells, loose edema of some acinar cells; increased infiltration of inflammatory cells in peritoneum; increased infiltration of inflammatory cells in spleen tissue, disordered and destroyed structure, unclear red and white matter junction. The above pathological changes in the peritoneal tissues of recipient mice transplanted with peritoneal macrophages overexpressing ZFP36L2 were significantly alleviated.
[0144] (2) Based on Fig.10 As shown, the spleen weight of peritoneal macrophage transplant recipient mice overexpressing ZFP36L2 after irradiation was significantly lower than that of peritoneal macrophage transplant recipient mice overexpressing irrelevant sequences (NC group), indicating that ZFP36L2 can alleviate the macrophage-mediated immune inflammatory response after radiation.
[0145] (3) Based on Fig.11 As shown, mice transplanted with PMs overexpressing ZFP36L2 had significantly less spleen apoptosis than mice transplanted with PMs overexpressing an irrelevant sequence, indicating that overexpression of ZFP36L2 in macrophages can alleviate macrophage-mediated peritoneal tissue damage in mice stimulated by radiation.
[0146] In summary, the macrophage mouse transplantation experiment found that by adjusting the expression level of ZFP36L2 in macrophages, radiation-induced cell damage and systemic inflammatory response can be alleviated, thereby providing new ideas for the treatment of radiation damage and a new scientific basis for the development of potential therapeutic strategies in the future, and has broad prospects for clinical application.
[0147] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. Any modifications, equivalent substitutions, improvements, etc. made within the spirit and principle of the present invention should be included in the protection scope of the present invention.
Claims
1. Use of ZFP36L2 in the preparation of drugs for treating and / or preventing radiation damage, It is characterized in that The gene sequence of ZFP36L2 is shown in SEQ ID NO.
1.
2. Application of a ZFP36L2 overexpressing macrophage transplantation mouse model to protect against radiation damage in screening drugs for treating and / or preventing radiation damage, It is characterized in that The gene sequence of ZFP36L2 is shown in SEQ ID NO.
1.
3. The use according to claim 2, It is characterized in that The construction of the macrophage transplantation mouse model includes: S1. construct a plasmid for overexpression of ZFP36L2. The gene sequence of ZFP36L2 is shown in SEQ ID NO. The gene sequence of ZFP36L2 is cloned into the vector pGPG-Lenti CMV Puro through 5' XbaI and 3' SalI, and the ZFP36L2 overexpression plasmid is packaged by lentivirus; S2. Primary peritoneal macrophages were extracted from donor mice for culture. ZFP36L2 was overexpressed by infecting the above-mentioned lentivirus, and peritoneal macrophages with stable expression of ZFP36L2 were selected, and irradiated for stimulation; the irradiated peritoneal macrophages were reinfused into the peritoneal cavity of recipient mice to obtain a macrophage transplantation mouse model.
Citation Information
Cited By
Application of CEBPD and FOS as ZFP36L2 transcriptional regulatory factors in development of radioactive injury treatment drug targets
CN119896725A
